Mirum Pharmaceuticals, Inc. - Common Stock (MIRM)

CUSIP: 604749101

Q3 2026 13F Holders as of 30 Sep 2026

Holder snapshot 6 signals
Share change
+18,185
SEC-reported price per share
$85.48
Number of holders
72
Value change
-$6,126,362
Number of buys
35
Number of sells
33
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
60,919,423

Security key

604749101

Report period

Q3 2026

Institutions

72

Top holders

10

Ownership snapshot

Top reported holders of MIRM - Mirum Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Janus Henderson Group Ltd.
Disclosed value leader
Janus Henderson Group Ltd.
Comparable rows
6/15
Latest evidence
30 Jun 2026
13D/G 13F 3/4/5 Lead comparable stake: 9.7% 9 rows are not safely comparable across share classes. 13D/G row: Janus Henderson Group Ltd. Showing 1-6 of 15 holder rows.

Quick read

Janus Henderson Group Ltd. leads the comparable SEC ownership view at 9.7%.

6 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Janus Henderson Group Ltd.'s linked filing trail.
Comparable ownership Top 5
Janus Henderson Group Ltd. 9.7%
Frazier Life Sciences IX, L.P. 6.8%
FMR LLC 6.2%
BlackRock, Inc. 5.7%
EVENTIDE ASSET MANAGEMENT, LLC 4.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Janus Henderson Group Ltd.
13D/G
9.7%
Reported 13D/G · 30 Jun 2026
$759,743,787
5,909,184 shares
-$20,072,863 30 Jun 2026
Frazier Life Sciences IX, L.P.
13D/G
Patrick J. Heron
6.8%
Reported 13D/G · 23 Jan 2026
$324,522,832
4,108,404 shares
+$29,477,804 23 Jan 2026
FMR LLC
13D/G 13F
Company
6.2%
Reported 13D/G · 30 Jun 2026
$485,718,308
3,777,851 shares
$0 30 Jun 2026
BlackRock, Inc.
13F 13D/G
Company
5.7%
Reported 13D/G · 31 Mar 2026
$513,944,677
4,390,063 shares
— 30 Jun 2026
EVENTIDE ASSET MANAGEMENT, LLC
13D/G 13F
Company
4.1%
Reported 13D/G · 31 Dec 2025
$165,372,042
2,093,582 shares
-$40,549,990 31 Dec 2025
BIOTECHNOLOGY VALUE FUND L P
13D/G
BVF PARTNERS L P/IL
3%
Reported 13D/G · 30 Sep 2025
$109,619,710
1,495,290 shares
$0 30 Sep 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
72
Shares
2,613,891
Rows available
72
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2026 vs Q2 2026 Across Filers

Q2 2026 holders
324
Q3 2026 holders
72
Holder diff
-252
Investor Q2 2026 Shares Q3 2026 Shares Share Diff Share Chg % Q2 2026 value Q3 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .